Skip to content
Open access

Chronic Spontaneous Urticaria Endotypes: Exploratory Proteomic Analysis in the Benralizumab ARROYO Study.

Oct 2026 · Clinical and Experimental Allergy · 0 citations · 9 references
Medicine

Abstract

In this post hoc analysis funded by AstraZeneca, benralizumab reduced eosinophil‐related protein biomarker expression. Benralizumab reduced eosinophil‐derived neurotoxin concentrations, which were dose‐independent and irrespective of BHRA status.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.